Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VRDN | US
-0.33
-1.36%
Healthcare
Biotechnology
30/06/2024
04/10/2024
23.92
24.17
24.50
23.80
Viridian Therapeutics Inc. a biotechnology company discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001 a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003 a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004 a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics Inc. and changed its name to Viridian Therapeutics Inc. in January 2021. Viridian Therapeutics Inc. is headquartered in Waltham Massachusetts.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
57.2%1 month
123.6%3 months
85.2%6 months
74.1%-
-
5.40
0.04
0.04
-3.18
4.97K
-
-250.21M
1.83B
1.83B
-
-100.26K
-
-
-53.97
5.13
15.64
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
4.31
Range1M
11.48
Range3M
12.73
Rel. volume
0.17
Price X volume
10.36M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Harmony Biosciences Holdings Inc. | HRMY | Biotechnology | 34.6 | 2.00B | -2.73% | 20.07 | 40.71% |
Maravai LifeSciences Holdings Inc | MRVI | Biotechnology | 7.89 | 1.99B | -0.13% | n/a | 128.60% |
Ligand Pharmaceuticals Incorporated | LGND | Biotechnology | 104.78 | 1.95B | 4.83% | 42.52 | 0.98% |
BEAM THERAPEUTICS INC. | BEAM | Biotechnology | 23.41 | 1.93B | -0.38% | n/a | 19.35% |
Galapagos NV | GLPG | Biotechnology | 29.19 | 1.92B | 2.89% | 55.25 | 0.00% |
Mirum Pharmaceuticals Inc | MIRM | Biotechnology | 39.26 | 1.87B | -5.37% | n/a | 138.24% |
Intellia Therapeutics Inc | NTLA | Biotechnology | 17.99 | 1.83B | -3.02% | n/a | 10.95% |
MannKind Corporation | MNKD | Biotechnology | 6.49 | 1.78B | 3.18% | 124.00 | -149.80% |
Certara Inc. | CERT | Biotechnology | 11.09 | 1.78B | -2.46% | n/a | 29.96% |
Kiniksa Pharmaceuticals Ltd | KNSA | Biotechnology | 24.48 | 1.74B | -0.20% | n/a | 2.62% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.18 | 0.76 | Cheaper |
Ent. to Revenue | 4,967.71 | 3,674.48 | Expensive |
PE Ratio | - | 38.01 | - |
Price to Book | 5.40 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 85.17 | 74.67 | Par |
Debt to Equity | 0.04 | -1.82 | Expensive |
Debt to Assets | 0.04 | 0.26 | Cheaper |
Market Cap | 1.83B | 3.73B | Emerging |